Add search app

.gitignore

@@ -0,0 +1,2 @@
+# Venv
+.env

app.py

@@ -0,0 +1,39 @@
+import streamlit as st
+import srsly
+
+def search(query):
+    results = []
+    for grant in grants:
+        if query in grant["tags"]:
+            results.append({
+                "title": grant["title"],
+                "tags": grant["tags"]
+            })
+    st.session_state["results"] = results
+
+st.header("Search 🔎 grants using MeSH 🔖")
+st.sidebar.header("Information ℹ")
+st.sidebar.write("A complete list of MeSH tags can be found here https://meshb.nlm.nih.gov/treeView")
+st.sidebar.write("The grants data can be found https://www.threesixtygiving.org/")
+st.sidebar.write("The model used to tag grants is https://huggingface.co/Wellcome/WellcomeBertMesh")
+
+if "grants" not in st.session_state:
+    st.session_state["grants"] = list(srsly.read_jsonl("tagged_grants.jsonl"))
+
+grants = st.session_state["grants"]
+
+query = st.text_input("", value="Malaria")
+st.button("Search 🔎", on_click=search, kwargs={"query": query})
+
+if "results" in st.session_state:
+    st.caption("Related MeSH terms")
+    unique_tags = list(set(list([tag for res in st.session_state["results"] for tag in res["tags"]])))
+    columns = st.columns(5)
+    for row_i in range(3):
+        for col_i, col in enumerate(columns):
+            with col:
+                tag_i = row_i*5 + col_i
+                if tag_i < len(unique_tags):
+                    tag = unique_tags[tag_i]
+                    st.button(tag, on_click=search, kwargs={"query": tag})
+    st.table(st.session_state["results"])

preprocess.py

@@ -0,0 +1,16 @@
+import json
+
+from tqdm import tqdm
+import typer
+
+def preprocess(data_path, processed_data_path):
+    with open(data_path) as f:
+        data = json.loads(f.read())
+
+    with open(processed_data_path, "w") as f:
+        for grant in tqdm(data["grants"]):
+            if any([org["name"] == "The Wellcome Trust" for org in grant["fundingOrganization"]]):
+                f.write(json.dumps(grant) + "\n")
+
+if __name__ == "__main__":
+    typer.run(preprocess)

requirements.txt

@@ -0,0 +1,2 @@
+streamlit==1.10.0
+srsly==2.4.3

tag.py

@@ -0,0 +1,35 @@
+import json
+
+from transformers import AutoModel, AutoTokenizer
+import srsly
+import typer
+
+
+def load_data(data_path, sample_size):
+    with open(data_path) as f:
+        data = json.loads(f.read())
+
+    return data
+
+
+def tag(data_path, tagged_data_path, sample_size: int = 10):
+    data = srsly.read_jsonl(data_path)
+    data = [next(data) for _ in range(sample_size)]
+
+    tokenizer = AutoTokenizer.from_pretrained("Wellcome/WellcomeBertMesh")
+    model = AutoModel.from_pretrained(
+        "Wellcome/WellcomeBertMesh", trust_remote_code=True
+    )
+
+    texts = [grant["title_and_description"] for grant in data]
+    inputs = tokenizer(texts, padding="max_length")
+    labels = model(**inputs, return_labels=True)
+
+    for i, tags in enumerate(labels):
+        data[i]["tags"] = tags
+
+    srsly.write_jsonl(tagged_data_path, data)
+
+
+if __name__ == "__main__":
+    typer.run(tag)

tagged_grants.jsonl

@@ -0,0 +1,10 @@
+{"id":"360G-Wellcome-221604_Z_20_Z","title":"Immunometabolic cross-talk in the inflamed diabetic heart","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Mark Caulfield","Internal ID":"221604/Z/20/Z","description":"Diabetic cardiomyopathy (dbCM) is a complication of type II diabetes (T2D), characterised by systemic inflammation, impaired cardiac function and disrupted metabolism. However, the impact of systemic inflammation on the development of the myocardial inflammation and cardiac metabolic derangement that lead to dbCM remain unknown. This study will address how chronic adaptive inflammation driven by systemic metabolic stress in T2D causes cardiac dysfunction. Specifically, I hypothesise that it is caused by inflammation due to T-cell infiltration and not by direct metabolic perturbations that can lead to impaired energetics (reduced PCr/ATP ratio). Specifically, the aim is to use integrated experimental approach combining metabolic analysis with T-cell phenotypic profiling in murine and human T2D to address three research challenges:\n\nA. Does infiltration of cardiotropic T-cells impair cardiac substrate plasticity and energetics in dbCM?\n\nB. Do myocardial succinate efflux and signalling via SUCNR1 promote cardiac Teff and/or Treg activation by modifying T-cell metabolism and do they enhance pro-inflammatory T-cell differentiation?\n\nC. Does stimulation of GCK-mediated glycolysis increase regulatory T-cell migration to the heart causing a switch in the nature of immune response from pro-inflammatory to immunosuppressive? Does the resultant reduction in myocardial exposure to pro-inflammatory cytokines improve cardiac function and mitochondrial performance? \n","plannedDates":[{"endDate":"2025-01-10T00:00:00+00:00","startDate":"2021-01-11T00:00:00+00:00","startDateDateOnly":"2021-01-11","endDateDateOnly":"2025-01-10"}],"amountAwarded":630613,"Financial Year":"2020/21","Lead Applicant":"Dr Dunja Aksentijevic","grantProgramme":[{"title":"Career Re-Entry Fellowship","title_keyword":"Career Re-Entry Fellowship"}],"Applicant Surname":"Aksentijevic","Partnership Value":630613,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Immunometabolic cross-talk in the inflamed diabetic heart Diabetic cardiomyopathy (dbCM) is a complication of type II diabetes (T2D), characterised by systemic inflammation, impaired cardiac function and disrupted metabolism. However, the impact of systemic inflammation on the development of the myocardial inflammation and cardiac metabolic derangement that lead to dbCM remain unknown. This study will address how chronic adaptive inflammation driven by systemic metabolic stress in T2D causes cardiac dysfunction. Specifically, I hypothesise that it is caused by inflammation due to T-cell infiltration and not by direct metabolic perturbations that can lead to impaired energetics (reduced PCr/ATP ratio). Specifically, the aim is to use integrated experimental approach combining metabolic analysis with T-cell phenotypic profiling in murine and human T2D to address three research challenges:\n\nA. Does infiltration of cardiotropic T-cells impair cardiac substrate plasticity and energetics in dbCM?\n\nB. Do myocardial succinate efflux and signalling via SUCNR1 promote cardiac Teff and/or Treg activation by modifying T-cell metabolism and do they enhance pro-inflammatory T-cell differentiation?\n\nC. Does stimulation of GCK-mediated glycolysis increase regulatory T-cell migration to the heart causing a switch in the nature of immune response from pro-inflammatory to immunosuppressive? Does the resultant reduction in myocardial exposure to pro-inflammatory cytokines improve cardiac function and mitochondrial performance? \n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Diabetes Mellitus, Type 2","Energy Metabolism","Glycolysis","Humans","Inflammation","Mice","T-Lymphocytes","T-Lymphocytes, Regulatory"]}
+{"id":"360G-Wellcome-221598_Z_20_Z","title":"Oral Ketamine Capsules - A new potential treatment for Depression. A pharmacokinetic and pharmacodynamic assessment of Ketamine and Metabolites in a dose-escalating, placebo-controlled clinical trial in healthy subjects.","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221598/Z/20/Z","description":"Neurocentrx has developed oral capsule formulations of Ketamine, aiming to be new treatments for Depression. Ketamine is a synthetic drug created in the 1960\u2019s. It is on the \"essential medicine\" list of the World Health Organisation (WHO), approved and licensed by health regulators worldwide as an injectable anaesthetic. More recently, and at sub-anaesthetic doses, clinical trials have shown that some patients with depression have a rapid response to injectable ketamine (hours or days). Most other anti-depressant medicines take many weeks to work. No oral ketamine products are currently available as a licensed medicine worldwide. Our project will assess oral capsules in healthy people in a clinical trial. We will assess absorption and excretion with increasing doses of drug and measure any side-effects. These data will be essential to accurately plan trials in depression patients where we will then look for benefits. Oral capsules could be used at home, and are hoped to be a cheaper treatment option, with fewer side-effects for patients. The summary above may be amended from time to time by mutual agreement of the Parties. For this clause agreement by email will be sufficient to render a valid amendment to the summary).","plannedDates":[{"endDate":"2022-04-10T00:00:00+00:00","startDate":"2020-11-09T00:00:00+00:00","startDateDateOnly":"2020-11-09","endDateDateOnly":"2022-04-10"}],"amountAwarded":498326,"Financial Year":"2019/20","Lead Applicant":"Dr Carmel Reilly","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Reilly","Partnership Value":498326,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Mario Juruena","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Neurocentrx-Pharma-Ltd","name":"Neurocentrx Pharma Ltd","addressCountry":"United Kingdom","id_and_name":"[\"Neurocentrx Pharma Ltd\", \"360G-Wellcome-ORG:Neurocentrx-Pharma-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Neurocentrx-Pharma-Ltd","name":"Neurocentrx Pharma Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Oral Ketamine Capsules - A new potential treatment for Depression. A pharmacokinetic and pharmacodynamic assessment of Ketamine and Metabolites in a dose-escalating, placebo-controlled clinical trial in healthy subjects. Neurocentrx has developed oral capsule formulations of Ketamine, aiming to be new treatments for Depression. Ketamine is a synthetic drug created in the 1960\u2019s. It is on the \"essential medicine\" list of the World Health Organisation (WHO), approved and licensed by health regulators worldwide as an injectable anaesthetic. More recently, and at sub-anaesthetic doses, clinical trials have shown that some patients with depression have a rapid response to injectable ketamine (hours or days). Most other anti-depressant medicines take many weeks to work. No oral ketamine products are currently available as a licensed medicine worldwide. Our project will assess oral capsules in healthy people in a clinical trial. We will assess absorption and excretion with increasing doses of drug and measure any side-effects. These data will be essential to accurately plan trials in depression patients where we will then look for benefits. Oral capsules could be used at home, and are hoped to be a cheaper treatment option, with fewer side-effects for patients. The summary above may be amended from time to time by mutual agreement of the Parties. For this clause agreement by email will be sufficient to render a valid amendment to the summary).","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Adult","Capsules","Dose-Response Relationship, Drug","Double-Blind Method","Humans","Ketamine","Research Design"]}
+{"id":"360G-Wellcome-221597_Z_20_Z","title":"The evaluation of novel GBS conjugates prepared from GBS capsular polysaccharides and GBS conserved surface proteins\u2019","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221597/Z/20/Z","description":"Group B Streptococcus (GBS) bacterial infection is a major health concern and a leading cause of sepsis and meningitis in infants, particularly in Africa. A promising prevention for GBS infection in newborns is maternal immunization with a GBS vaccine. Currently no vaccine for GBS is available. Several conjugate GBS vaccines using GBS surface-expressed polysaccharides linked to carrier proteins are under development. We are proposing a novel vaccine design using GBS polysaccharides conjugated to GBS conserved surface proteins which induce immune responses in infected individuals, making them potential candidates as carrier proteins for novel GBS vaccines. It combines two virulence factors of GBS with the potential to provide not only enhanced overall protection compared to traditional conjugate vaccines but also to potentially provide protection against those serotypes not included in the vaccine. It could lead to the development of an affordable and cost-effective vaccine that protects against all GBS serotypes.","plannedDates":[{"endDate":"2022-10-30T00:00:00+00:00","startDate":"2021-05-03T00:00:00+00:00","startDateDateOnly":"2021-05-03","endDateDateOnly":"2022-10-30"}],"amountAwarded":398043,"Financial Year":"2019/20","Lead Applicant":"Dr Seanette Wilson","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Wilson","Partnership Value":398043,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Gaurav Kwatra","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Biovac-Institute","name":"The Biovac Institute","addressCountry":"South Africa","id_and_name":"[\"The Biovac Institute\", \"360G-Wellcome-ORG:The-Biovac-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Biovac-Institute","name":"The Biovac Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The evaluation of novel GBS conjugates prepared from GBS capsular polysaccharides and GBS conserved surface proteins\u2019 Group B Streptococcus (GBS) bacterial infection is a major health concern and a leading cause of sepsis and meningitis in infants, particularly in Africa. A promising prevention for GBS infection in newborns is maternal immunization with a GBS vaccine. Currently no vaccine for GBS is available. Several conjugate GBS vaccines using GBS surface-expressed polysaccharides linked to carrier proteins are under development. We are proposing a novel vaccine design using GBS polysaccharides conjugated to GBS conserved surface proteins which induce immune responses in infected individuals, making them potential candidates as carrier proteins for novel GBS vaccines. It combines two virulence factors of GBS with the potential to provide not only enhanced overall protection compared to traditional conjugate vaccines but also to potentially provide protection against those serotypes not included in the vaccine. It could lead to the development of an affordable and cost-effective vaccine that protects against all GBS serotypes.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Bacterial","Bacterial Capsules","Humans","Serogroup","Streptococcal Infections","Streptococcal Vaccines","Streptococcus agalactiae","Vaccines, Conjugate"]}
+{"id":"360G-Wellcome-221595_Z_20_Z","title":"Preclinical Toxicology Testing and IND application for a Novel Cholera Conjugate Vaccine","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221595/Z/20/Z","description":"Cholera is a disease of inequity that continues to disproportionately affect the world\u2019s poorest and\nmost vulnerable people. An oral cholera vaccine (OCV) is available and in use around the world,\nbut it has lower efficacy in young children than in adults and a relatively short duration of protection\nnecessitating re-vaccination every few years. We are developing a new conjugate vaccine that\noffers the promise of improved efficacy in all age groups, including those less than 5 years, and an\nextended duration of protection, thus reducing the requirements for repetitive vaccination to sustain\npopulation immunity. It can be implemented in place of OCV or as a complementary tool to prevent\nor limit outbreaks in high risk settings, and build enduring population immunity that will costeffectively\ncontrol cholera over the decades required to build definitive public health capacities in at\nrisk countries.","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":456865,"Financial Year":"2019/20","Lead Applicant":"Dr Julia Lynch","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Lynch","Partnership Value":456865,"Approval Committee":"Innovator Awards Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute","addressCountry":"Korea, South","id_and_name":"[\"International Vaccine Institute\", \"360G-Wellcome-ORG:International-Vaccine-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Preclinical Toxicology Testing and IND application for a Novel Cholera Conjugate Vaccine Cholera is a disease of inequity that continues to disproportionately affect the world\u2019s poorest and\nmost vulnerable people. An oral cholera vaccine (OCV) is available and in use around the world,\nbut it has lower efficacy in young children than in adults and a relatively short duration of protection\nnecessitating re-vaccination every few years. We are developing a new conjugate vaccine that\noffers the promise of improved efficacy in all age groups, including those less than 5 years, and an\nextended duration of protection, thus reducing the requirements for repetitive vaccination to sustain\npopulation immunity. It can be implemented in place of OCV or as a complementary tool to prevent\nor limit outbreaks in high risk settings, and build enduring population immunity that will costeffectively\ncontrol cholera over the decades required to build definitive public health capacities in at\nrisk countries.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Adolescent","Adult","Child","Child, Preschool","Cholera","Cholera Vaccines","Humans"]}
+{"id":"360G-Wellcome-221590_Z_20_Z","title":"AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment ","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221590/Z/20/Z","description":"Conventional evaluation of new medicines is not fast enough for a pandemic. Our aim is to accelerate this process, rapidly identifying which drugs are safe and potentially effective treatments for COVID-19. AGILE is an innovative, multi-arm, multi-dose, multi-stage Phase I/IIa Bayesian adaptive platform protocol to evaluate experimental COVID-19 therapies, and to funnel plausible candidates into large Phase IIb/III trials such as RECOVERY and SOLIDARITY. We will efficiently eliminate candidates with little or no prospect of clinical success.\n\nAGILE will recruit COVID-19 patients into very early phase clinical studies, including first-in-human. The innovative design allows us to move seamlessly from first-in-human use to finding the optimal dose for COVID-19 patients. The trial is pragmatic (requiring only small numbers of patients), adaptive (so that the right drug is tested in the right group of COVID-19 patients, either in the community or in hospital) and statistically efficient (so that several drugs can be tested in parallel, making best use of a small number of patients). Our primary focus is population-scalable antiviral drugs for early treatment of COVID-19, for which we will recruit primarily in the community. AGILE has full regulatory and ethics approvals in the UK.\n \n","plannedDates":[{"endDate":"2023-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2023-01-31"}],"amountAwarded":3069077,"Financial Year":"2019/20","Lead Applicant":"Prof Saye Khoo","grantProgramme":[{"title":"Therapeutics Accelerator ","title_keyword":"Therapeutics Accelerator "}],"Applicant Surname":"Khoo","Partnership Value":3069077,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Richard Fitzgerald, Prof Gareth Griffiths, Prof Sir Munir Pirmohamed, Dr Mohammed Lamorde, Prof Catherine Orrell, Prof David Lalloo, Dr Shevin Jacob, Dr Thomas Fletcher, Prof Andrew Owen, Prof Francois Venter, Prof Thomas Jaki, Dr Bella Starling, Prof William Greenhalf, Sir Michael Jacobs","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment  Conventional evaluation of new medicines is not fast enough for a pandemic. Our aim is to accelerate this process, rapidly identifying which drugs are safe and potentially effective treatments for COVID-19. AGILE is an innovative, multi-arm, multi-dose, multi-stage Phase I/IIa Bayesian adaptive platform protocol to evaluate experimental COVID-19 therapies, and to funnel plausible candidates into large Phase IIb/III trials such as RECOVERY and SOLIDARITY. We will efficiently eliminate candidates with little or no prospect of clinical success.\n\nAGILE will recruit COVID-19 patients into very early phase clinical studies, including first-in-human. The innovative design allows us to move seamlessly from first-in-human use to finding the optimal dose for COVID-19 patients. The trial is pragmatic (requiring only small numbers of patients), adaptive (so that the right drug is tested in the right group of COVID-19 patients, either in the community or in hospital) and statistically efficient (so that several drugs can be tested in parallel, making best use of a small number of patients). Our primary focus is population-scalable antiviral drugs for early treatment of COVID-19, for which we will recruit primarily in the community. AGILE has full regulatory and ethics approvals in the UK.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antiviral Agents","Bayes Theorem","Clinical Trials, Phase I as Topic","Humans","Research Design"]}
+{"id":"360G-Wellcome-221589_Z_20_Z","title":"Development of a Universal Group A Streptococcus Glycoconjugate Vaccine","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221589/Z/20/Z","description":"The pathogenic bacterium Group A Streptococcus (GAS) causes a range of infections, ranging from mild tonsillitis to invasive necrotising fasciitis, sepsis and toxic shock syndrome. GAS also induces severe long-lasting autoimmune disease, including rheumatic heart disease. Annually, GAS infections kill  > 500,000 people worldwide. While antibiotics are considered a reliable first line of defence against GAS infections, globally emerging antimicrobial resistance is an enormous threat. The WHO has included GAS in its vaccine priority list to finally reduce the high mortality and morbidity. We will use our developed novel modular system to produce the first dual-acting and lowcost GAS vaccine candidates targeting all  > 150 GAS strains. Our approach provides the first robust and affordable solution to target and prevent GAS infections, urgently required for the global population and in particular the people in low-income countries.","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":402298,"Financial Year":"2019/20","Lead Applicant":"Dr Helge Dorfmueller","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Dorfmueller","Partnership Value":402298,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Prof Brendan Wren","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of a Universal Group A Streptococcus Glycoconjugate Vaccine The pathogenic bacterium Group A Streptococcus (GAS) causes a range of infections, ranging from mild tonsillitis to invasive necrotising fasciitis, sepsis and toxic shock syndrome. GAS also induces severe long-lasting autoimmune disease, including rheumatic heart disease. Annually, GAS infections kill  > 500,000 people worldwide. While antibiotics are considered a reliable first line of defence against GAS infections, globally emerging antimicrobial resistance is an enormous threat. The WHO has included GAS in its vaccine priority list to finally reduce the high mortality and morbidity. We will use our developed novel modular system to produce the first dual-acting and lowcost GAS vaccine candidates targeting all  > 150 GAS strains. Our approach provides the first robust and affordable solution to target and prevent GAS infections, urgently required for the global population and in particular the people in low-income countries.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Streptococcal Infections","Streptococcal Vaccines","Streptococcus pyogenes"]}
+{"id":"360G-Wellcome-221586_Z_20_Z","title":"\u2018DuoChol: A low-cost, thermostable dry formulation whole-cell / B-subunit enterocoated capsule oral cholera vaccine.\u2019","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221586/Z/20/Z","description":"\"The Project aims at completion of the preclinical development of a new, improved oral cholera vaccine (OCV), DuoChol. This is a proposed thermostable OCV consisting of a lyophilized mixture of formalin-killed V. cholerae O1 Ogawa and Inaba strain whole-cells and cholera toxin B-subunit (rCTB) formulated in an enterocoated capsule. The two strains are isogenic except for the single serotype determining wbeT gene, and this allows them to be co-cultured to high density, which together with inexpensive high-yield rCTB production ensures low-cost manufacturing. The Project will build a solid platform for the subsequent clinical development of DuoChol, whose affordable cost, practical formulation and higher efficacy compared with current OCVs will make this a very attractive OCV for use in national cholera control programs and ideal for use in cholera outbreaks where rapid deployment and maximal early efficacy is of the essence.","plannedDates":[{"endDate":"2022-07-29T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2022-07-29"}],"amountAwarded":1130853,"Financial Year":"2019/20","Lead Applicant":"Prof Jan Holmgren","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Applicant Surname":"Holmgren","Partnership Value":1130853,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","Other Applicant(s)":"Dr Michael Lebens, Dr Manuela Terrinoni, Dr Stefan Nordqvist","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Gothenburg","name":"University of Gothenburg","addressCountry":"Sweden","id_and_name":"[\"University of Gothenburg\", \"360G-Wellcome-ORG:University-of-Gothenburg\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Gothenburg","name":"University of Gothenburg"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u2018DuoChol: A low-cost, thermostable dry formulation whole-cell / B-subunit enterocoated capsule oral cholera vaccine.\u2019 \"The Project aims at completion of the preclinical development of a new, improved oral cholera vaccine (OCV), DuoChol. This is a proposed thermostable OCV consisting of a lyophilized mixture of formalin-killed V. cholerae O1 Ogawa and Inaba strain whole-cells and cholera toxin B-subunit (rCTB) formulated in an enterocoated capsule. The two strains are isogenic except for the single serotype determining wbeT gene, and this allows them to be co-cultured to high density, which together with inexpensive high-yield rCTB production ensures low-cost manufacturing. The Project will build a solid platform for the subsequent clinical development of DuoChol, whose affordable cost, practical formulation and higher efficacy compared with current OCVs will make this a very attractive OCV for use in national cholera control programs and ideal for use in cholera outbreaks where rapid deployment and maximal early efficacy is of the essence.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Cholera","Cholera Vaccines","Humans","Vibrio cholerae"]}
+{"id":"360G-Wellcome-221582_Z_20_Z","title":"Predicting CBT response from fear conditioning","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221582/Z/20/Z","description":"Responses to psychological interventions for anxiety vary greatly. Clients and clinicians want better ways to predict outcomes. One contender is fear extinction, the process through which exposure, the \"behavioural\" part of Cognitive Behavioural Therapy (CBT) is thought to work. Whilst there are robust differences in fear extinction between individuals with anxiety disorders versus controls, evidence that extinction predicts CBT response is modest. \n\n We first became interested in fear extinction as a mechanistic tool to help understand how CBT works. In order to build algorithms from numerous potential predictors, including fear extinction, we needed to undertake fear conditioning at a scale. We developed a smartphone App FLARe, that remotely delivers a fear conditioning paradigm. Our validation studies showed that fear extinction data from our App mirror that from gold-standard in-lab delivery. \n\nWe now want to test the extent to which App-delivered fear extinction data predicts CBT response. We will assess young adults with high anxiety using our App before enrolling them in CBT. We will test the strength of correlation between fear extinction and treatment outcome. We will also explore the extent to which this association is stronger in specific sub-groups (e.g. those who completed more exposure homework during treatment).\n","plannedDates":[{"endDate":"2022-04-01T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2022-04-01"}],"amountAwarded":347602,"Financial Year":"2019/20","Lead Applicant":"Prof Thalia Eley","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Eley","Partnership Value":347602,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Colette Hirsch, Prof Gerome Breen","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Predicting CBT response from fear conditioning Responses to psychological interventions for anxiety vary greatly. Clients and clinicians want better ways to predict outcomes. One contender is fear extinction, the process through which exposure, the \"behavioural\" part of Cognitive Behavioural Therapy (CBT) is thought to work. Whilst there are robust differences in fear extinction between individuals with anxiety disorders versus controls, evidence that extinction predicts CBT response is modest. \n\n We first became interested in fear extinction as a mechanistic tool to help understand how CBT works. In order to build algorithms from numerous potential predictors, including fear extinction, we needed to undertake fear conditioning at a scale. We developed a smartphone App FLARe, that remotely delivers a fear conditioning paradigm. Our validation studies showed that fear extinction data from our App mirror that from gold-standard in-lab delivery. \n\nWe now want to test the extent to which App-delivered fear extinction data predicts CBT response. We will assess young adults with high anxiety using our App before enrolling them in CBT. We will test the strength of correlation between fear extinction and treatment outcome. We will also explore the extent to which this association is stronger in specific sub-groups (e.g. those who completed more exposure homework during treatment).\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Anxiety Disorders","Cognitive Behavioral Therapy","Extinction, Psychological","Fear","Female","Humans","Male","Mobile Applications","Smartphone","Young Adult"]}
+{"id":"360G-Wellcome-221579_Z_20_Z","title":"Understanding the impact of COVID-19 on bacterial sepsis, antibiotic consumption and stewardship, and antimicrobial resistance","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221579/Z/20/Z","description":"This study aims to address the following questions through a global network of hospitals: \n\n\n Is there evidence for a reduction in the total number or rates (per 1,000 inpatients) of blood cultures taken over twelve months?\n Has there been changes in antimicrobial usage (quantitative and qualitative)? \n Are there major changes in antibiotic resistance profiles from major pathogens?\n Have there been changes in antimicrobial stewardship and why? \n What is the overall change in the management of these patients?\n What is the impact of COVID-19 on infection control practices during the pandemic? \n Is there any evidence of reduction in nosocomial infections and bacterial outbreaks during the COVID-19 pandemic? \n\n\nWe will collect clinical (patient-based [severe pneumonia, ARDS, sepsis patients], hospital and microbiological data from 11 countries (UK, Switzerland, Italy, Brazil, Nigeria, Malawi, Turkey, Iran, India, Bangladesh and South Korea).  \n\nOur primary outcome will be to determine if there has been a reduction in blood cultures taken. Secondary outcomes include whether 1. changes in antimicrobial usage 2. major changes in antibiotic resistance profiles from major pathogens in hospitals during COVID-19 and correlate resistance profiles with antibiotic usage. 3. changes in infection control practices and other aspects of sepsis management behaviour during the COVID-19 pandemic.\n","plannedDates":[{"endDate":"2022-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2022-08-31"}],"amountAwarded":765283,"Financial Year":"2019/20","Lead Applicant":"Prof Timothy Walsh","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Walsh","Partnership Value":765283,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Stephan Harbarth, Dr Catrin Moore, Dr Ly-Mee Yu, Prof Nicholas Feasey, Prof Ben Cooper, Prof Christiane Dolecek","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the impact of COVID-19 on bacterial sepsis, antibiotic consumption and stewardship, and antimicrobial resistance This study aims to address the following questions through a global network of hospitals: \n\n\n Is there evidence for a reduction in the total number or rates (per 1,000 inpatients) of blood cultures taken over twelve months?\n Has there been changes in antimicrobial usage (quantitative and qualitative)? \n Are there major changes in antibiotic resistance profiles from major pathogens?\n Have there been changes in antimicrobial stewardship and why? \n What is the overall change in the management of these patients?\n What is the impact of COVID-19 on infection control practices during the pandemic? \n Is there any evidence of reduction in nosocomial infections and bacterial outbreaks during the COVID-19 pandemic? \n\n\nWe will collect clinical (patient-based [severe pneumonia, ARDS, sepsis patients], hospital and microbiological data from 11 countries (UK, Switzerland, Italy, Brazil, Nigeria, Malawi, Turkey, Iran, India, Bangladesh and South Korea).  \n\nOur primary outcome will be to determine if there has been a reduction in blood cultures taken. Secondary outcomes include whether 1. changes in antimicrobial usage 2. major changes in antibiotic resistance profiles from major pathogens in hospitals during COVID-19 and correlate resistance profiles with antibiotic usage. 3. changes in infection control practices and other aspects of sepsis management behaviour during the COVID-19 pandemic.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Bacterial Infections","Cross Infection","Drug Resistance, Bacterial","Drug Utilization","Hospitals","Humans","Sepsis"]}
+{"id":"360G-Wellcome-221576_Z_20_Z","title":"Unit for Health Evidence and Policy ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221576/Z/20/Z","description":"This proposal outlines the establishment of a pilot Unit for Health Evidence and Policy within CDT-Africa, a World Bank African Centre for Excellence based at Addis Ababa University, Ethiopia. Building on strong operational research into Neglected Tropical Diseases, and existing relationships within Ethiopia\u2019s Ministry of Health, the Unit for Health Policy and Evidence will identify challenges to research uptake, pilot and evaluate an approach to improving research uptake, and produce a framework to guide future research uptake in this setting and possibly more broadly.\n\nThe pilot Unit for Health Policy and Evidence will be a 12-month project, divided into two Periods. Period 1 will comprise stakeholder consultation through two Theory of Change workshops and other interviews as necessary. During Period 2, research uptake in an NTD area defined in Period 1 will be evaluated using the Diversity Approach (see below). A Research Uptake Framework will be developed and a dissemination workshop held with key national and international stakeholders.\n \n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":48135,"Financial Year":"2019/20","Lead Applicant":"Dr Abebaw Fekadu","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Fekadu","Partnership Value":96271,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Addis-Ababa-University","name":"Addis Ababa University","addressCountry":"Ethiopia","id_and_name":"[\"Addis Ababa University\", \"360G-Wellcome-ORG:Addis-Ababa-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Addis-Ababa-University","name":"Addis Ababa University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unit for Health Evidence and Policy  This proposal outlines the establishment of a pilot Unit for Health Evidence and Policy within CDT-Africa, a World Bank African Centre for Excellence based at Addis Ababa University, Ethiopia. Building on strong operational research into Neglected Tropical Diseases, and existing relationships within Ethiopia\u2019s Ministry of Health, the Unit for Health Policy and Evidence will identify challenges to research uptake, pilot and evaluate an approach to improving research uptake, and produce a framework to guide future research uptake in this setting and possibly more broadly.\n\nThe pilot Unit for Health Policy and Evidence will be a 12-month project, divided into two Periods. Period 1 will comprise stakeholder consultation through two Theory of Change workshops and other interviews as necessary. During Period 2, research uptake in an NTD area defined in Period 1 will be evaluated using the Diversity Approach (see below). A Research Uptake Framework will be developed and a dissemination workshop held with key national and international stakeholders.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Ethiopia","Health Policy","Humans","Pilot Projects","Policy Making","Universities"]}